Motixafortide acetate is under clinical development by BioLineRx and currently in Pre-Registration for Multiple Myeloma (Kahler Disease). According to GlobalData, Pre-Registration drugs for Multiple Myeloma (Kahler Disease) have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Motixafortide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Motixafortide acetate overview

Motixafortide is under development for the treatment of hematological cancers including chronic myeloid leukemia, metastatic adenocarcinoma of the pancreas, non-Hodgkin's lymphoma, neuroblastoma, melanoma, thrombocytopenia, aplastic anemia (AA), gastric cancer, adenocarcinoma of gastric or gastroesophageal junction, hypoplastic myelodysplastic syndrome, metastatic pancreatic adenocarcinoma, small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, multiple myeloma, sickle cell disease and acute respiratory distress syndrome (ARDS) secondary to COVID-19, acute myeloid leukemia and other respiratory viral infections. The drug candidate is administered through subcutaneous and intravenous route. BL-8040 is a short peptide. It acts by targeting chemokine (C-X-C Motif) receptor 4 (CXCR4). The company was developing relapsed/refractory acute myeloid leukemia (AML) and squamous non-small cell lung cancer (first and third-line therapy), hematopoietic stem cell transplantation.

BioLineRx overview

BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML), and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel.

For a complete picture of Motixafortide acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.